Explore the comprehensive comorbidities of Duchenne Muscular Dystrophy, including cognitive, respiratory, and nutritional challenges faced by patients.
Videos
The pair of neurologists highlight key advances needed in imaging, trial design, and preclinical modeling to drive remyelination breakthroughs in MS.
Duchenne Muscular Dystrophy progresses with motor delays, varying deterioration rates, and impacts multiple organs, highlighting the need for early intervention.
The vice president and franchise lead of Autoimmune at Hansa Biopharma provided clinical insights on latest phase 2 safety and efficacy data on imlifidase, an IgG-cleaving antibody, in Guillain-Barré syndrome. [WATCH TIME: 3 minutes]
In this episode, a duo of neurologists examine the plausibility, limitations, and risks of holistic approaches to remyelination—and what patients should prioritize or avoid.
Panelists Ari Green, MD, and Paul Tesar, PhD, explore the scientific rationale and clinical complexity behind promising remyelination agents currently in development for multiple sclerosis.
Episode 4 covers how aging and disease duration impact remyelination potential and the strategies for targeting repair across the multiple sclerosis spectrum.
In this episode, panelists outline the key scientific and clinical challenges in translating remyelination research into effective therapies for patients with MS.
Neurology News Network. for the week ending May 24, 2025. [WATCH TIME: 4 minutes]
Neurologists Ari Green, MD, and Paul Tesar, PhD, discuss the current limitations of remyelination assessment tools in MS and highlight efforts to develop more reliable clinical measures.
A panelist discusses how managing chronic insomnia often requires tailored treatments like dual orexin receptor antagonists (DORAs), which offer long-term benefits for sleep maintenance without the risk of tolerance or rebound insomnia, while emphasizing patient counseling and realistic expectations for gradual improvement.
Panelists discuss how medical professionals have incorporated continuous subcutaneous infusion systems into their clinical practice.
Panelists discuss how medical professionals view continuous subcutaneous infusion systems for managing Parkinson disease and their evolving role in treatment timing.
A panelist discusses how dual orexin receptor antagonists (DORAs) provide a novel and balanced approach to treating insomnia by targeting orexin receptors to reduce wakefulness without causing the broad central nervous system suppression seen with traditional sleep aids.
Enhancing Alzheimer Care in Asian and Pacific Islander Communities Through RCASIA: Brad Kamitaki, MD
The assistant professor of neurology at Robert Wood Johnson Medical School talked about a collaborative initiative that aims to address AD disparities in Asian and Pacific Islander American populations. [WATCH TIME: 3 minutes]
A panelist discusses how the phase 2b ENGAGE-E-001 study highlights Staccato alprazolam as an effective and well-tolerated option for rapid seizure termination, emphasizing its quick onset of action and potential benefits, while also cautioning about adverse effects such as sedation and respiratory depression in certain patients.
In this initial episode, experts Ari Green, MD, and Paul Tesar, PhD, break down the biological foundation and therapeutic importance of remyelination in multiple sclerosis.
Panelists discuss how variable number tandem repeats (VNTR) 3/2 polymorphisms in the FCGRT gene may affect FcRn levels, immunoglobulin G (IgG) half-life, and the effectiveness of intravenous immunoglobulin (IVIg) therapy in chronic inflammatory demyelinating polyneuropathy (CIDP), highlighting early real-world evidence suggesting that genetic testing could help personalize treatment strategies to optimize outcomes for patients based on their specific genotypes.
Panelists discuss how biomarkers, such as neurofilament light chain (NfL), autoantibodies, and inflammatory markers, have potential in enhancing chronic inflammatory demyelinating polyneuropathy (CIDP) diagnosis and treatment monitoring, but emphasize that their use remains experimental, and a comprehensive approach integrating clinical assessments and electrophysiological findings is essential for optimal patient care.
The vice president and franchise lead of Autoimmune at Hansa Biopharma discussed the rapid, antibody-cleaving mechanism of imlifidase and its potential to address unmet needs in Guillain-Barré syndrome. [WATCH TIME: 3 minutes]
The neurologist at the Hospital de la Santa Creu, in Barcelona, Spain, outlined the goals and significance of the VITALIZE and MOBILIZE phase 3 trials evaluating riliprubart in standard-of-care and treatment-refractory CIDP populations. [WATCH TIME: 3 minutes]
Panelists discuss how continuous subcutaneous infusion systems should be strategically positioned within Parkinson disease management, typically as options for patients with advanced disease experiencing motor fluctuations despite optimized oral therapy.
An expert discusses strategies to lower the age of Duchenne muscular dystrophy (DMD) diagnosis, emphasizing the importance of universal newborn screening with the testing of creatine kinase (CK) levels, clinician recognition of motor red flags such as the Gower sign, early neurology referrals, and incorporating CK level testing in cognitive delay evaluations to enable timely therapeutic intervention and improve long-term outcomes.
An expert discusses the typical presentation and diagnosis of Duchenne muscular dystrophy (DMD) around ages 5 to 6, highlighting early signs such as motor delays, Gower sign, and developmental concerns, while emphasizing the importance of newborn screening, clinician awareness, and developmental monitoring to enable earlier intervention and improved outcomes.
The chair of the Women’s Sleep Health Task Force at the American Academy of Sleep Medicine talked about how hormonal changes across a woman’s lifespan influence the prevalence of sleep disorders. [WATCH TIME: 4 minutes]
Panelists discuss how the newly FDA-approved continuous subcutaneous levodopa infusion system (foscarbidopa/foslevodopa) offers another advanced treatment option, exploring the ideal candidates for these continuous infusion therapies based on disease characteristics, previous treatment responses, and patient preferences.
The neurologist at the Hospital de la Santa Creu, in Barcelona, Spain, provided clinical context on sustained responses and new biomarker findings from exploratory phase 2 data on riliprubart in CIDP. [WATCH TIME: 4 minutes]
The president-elect of the Peripheral Nerve Society provided clinical context the mechanism and clinical relevance of riliprubart, a targeted complement inhibitor in development for chronic inflammatory demyelinating polyneuropathy. [WATCH TIME: 3 minutes]
Panelists discuss how emerging therapeutic targets, including amyloid-beta plaques, tau protein aggregation, inflammation modulation, and mitochondrial dysfunction, offer promising approaches for disease-modifying treatments in early Alzheimer disease.
Panelists discuss how recent advances in Alzheimer disease, including amyloid-targeting therapies like lecanemab and donanemab, along with the growing role of blood-based biomarkers for early diagnosis and monitoring, are transforming treatment paradigms, enabling disease modification and personalized care while improving accessibility and reducing barriers to diagnosis.
